Determination of Immunoglobulin A against Gardnerella vaginalis Hemolysin, Sialidase, and Prolidase Activities in Vaginal Fluid: Implications for Adverse Pregnancy Outcomes by Cauci, S et al.
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2003, p. 435–438 Vol. 41, No. 1
0095-1137/03/$08.000 DOI: 10.1128/JCM.41.1.435–438.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Determination of Immunoglobulin A against Gardnerella vaginalis
Hemolysin, Sialidase, and Prolidase Activities in Vaginal Fluid:
Implications for Adverse Pregnancy Outcomes
Sabina Cauci,1* Poul Thorsen,2 Diana E. Schendel,3 Annie Bremmelgaard,4
Franco Quadrifoglio,1 and Secondo Guaschino5
Department of Biomedical Sciences and Technologies, School of Medicine, University of Udine, Udine,1 and Obstetric and
Gynecologic Unit, Department of Reproductive and Development Sciences, IRCCS Burlo Garofolo Hospital, University
of Trieste, Trieste,5 Italy; Department of Epidemiology and Social Medicine and Danish Epidemiology Science
Centre, Aarhus University, Aarhus,2 and Department of Clinical Microbiology, Frederiksberg Hospital,
Copenhagen,4 Denmark; and National Center on Birth Defects and Developmental
Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia3
Received 22 July 2002/Returned for modification 18 September 2002/Accepted 24 October 2002
A nested case-control study of low birth weight and preterm delivery was performed with singleton women.
Immunoglobulin A (IgA) against the Gardnerella vaginalis hemolysin (anti-Gvh IgA) and sialidase and proli-
dase activities were determined in vaginal fluid at 17 weeks of gestation. Sialidase positivity and bacterial
vaginosis with high prolidase activity were associated with 2- and 11-fold increased risks for low birth weight,
respectively. No woman with bacterial vaginosis plus a strong anti-Gvh IgA response had an adverse outcome.
Low birth weight (LBW; 2,500 g), resulting primarily from
preterm delivery (PTD; spontaneous delivery before 37 weeks
of gestation [29]), is the strongest risk factor for neonatal
mortality and morbidity (14, 20). Bacterial vaginosis (BV) is
associated with adverse pregnancy outcomes (15, 17, 22–24,
26), but few women with BV have LBW or PTD infants (15).
Identification of more specific predictive markers than a mere
BV diagnosis could indicate which women would benefit from
antibiotic intervention (4, 32).
BV is characterized by a decrease in lactobacillus coloniza-
tion and overgrowth of many anaerobic or facultative species
(1, 5, 13, 30), such as Gardnerella vaginalis. Immunoglobulins A
(IgAs) against the hemolytic G. vaginalis toxin (Gvh) and siali-
dase and prolidase activities have been measured in the vaginal
fluid of BV-positive women (3, 5–11, 16, 22, 27, 28, 33). We
conducted a nested case-control study to determine whether
sialidase and prolidase activities, combined with anti-Gvh IgA,
can identify BV- and/or G. vaginalis-positive pregnant women
at risk for producing LBW and PTD infants.
We selected 579 women from a Danish regional cohort of
2,846 singleton pregnant women prospectively enrolled from
1992 to 1994 (29, 30). (Appropriate informed consent was
obtained, and clinical research was conducted in accordance
with the guidelines for human experimentation of the authors’
institutions.) Eighty-six PTD and 116 LBW cases were suitable
for analysis; 40 PTD cases were also LBW cases. A control
group of 417 women delivering normal birth weight babies at
term (NTD) was randomly selected. The mean gestational age
at enrollment was 16 weeks 5 days (range, 7 weeks 4 days to 24
weeks).
BV was clinically diagnosed by Amsel criteria (1, 30). Vag-
inal fluid samples were collected with a sterile cotton-tipped
swab, inoculated into 1 ml of sterile saline containing 2% calf
serum, and immediately frozen to 80°C.
Vaginal flora were determined by culture of cervicovaginal
swabs by routine methods (19, 30). The term Bacteroides group
was used for isolates of Bacteroides spp., Prevotella spp., Por-
phyromonas spp., and the Bacteroides fragilis group. The re-
maining isolates were collectively assigned to the nonspecified
group of anaerobic bacteria. Mobiluncus spp. were not identi-
fied (19).
Healthy controls were 133 women without bacteria other
than lactobacilli. Cutoff values for sialidase, prolidase, and
anti-Gvh IgA were determined in these women as follows: an
anti-Gvh IgA (6) value below a threshold of 392 millioptical
density (mOD) (mean value of the anti-Gvh IgA in healthy
controls plus 1 standard deviation [SD]) was considered no
response, a value of 392 and 784 mOD (two times the
cutoff) was considered a low response, and a value of 784
mOD was considered a high response.
Sialidase specific activity (9) was expressed in nanomoles of
methoxyphenol produced. A value below the 1 cutoff (mean
of healthy controls plus 1 SD) was considered no activity, a
value of0.19 nmol (1 cutoff) was considered positive, and
a value of 5.00 nmol (2 cutoff) was considered high (7).
Prolidase activity (7) was scored as follows: no activity, 22
mOD (mean of healthy controls plus 1 SD); positive, 22
mOD (1 cutoff); high, 2,000 mOD (2 cutoff) (11).
Univariate comparisons of proportions were carried out by
using Fisher’s exact test. P values of 0.05 were considered
statistically significant. Odds ratios (ORs) and 95% confidence
intervals (CIs) were calculated to estimate the risk for LBW
and PTD. Two-tailed Spearman rho coefficients were used to
examine the correlations between continuous variables. The
SPSS software package was used for analyses of data. Because
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of the low number of adverse pregnancy outcome cases, a
multivariate analysis was not performed.
Table 1 shows that positive sialidase (1 cutoff) was sig-
nificantly associated with LBW among women with BV, among
women positive for G. vaginalis, or overall. Only high prolidase
values (2 cutoff) were significantly associated with LBW
among women with BV, among women positive for G. vagina-
lis, or overall. A similar trend was found for PTD, but only the
OR for G. vaginalis positivity plus high prolidase activity was
significant.
Table 2 shows that the LBW risk appeared much lower in
women colonized by G. vaginalis with a high anti-Gvh IgA
response; the PTD risk also tended to be lower. The LBW risk
was elevated two- to threefold in all subgroups of women who
had a low or no anti-Gvh IgA response. Considering G. vagi-
nalis and nonspecified anaerobes, the risk for LBW was nearly
fivefold higher for women with low or no anti-Gvh IgA re-
sponse. However, a high anti-Gvh IgA response appeared pro-
tective, as no cases of either LBW or PTD were found in any
subgroups of women positive for G. vaginalis plus other micro-
organisms. No woman had a high anti-Gvh IgA response and
sialidase or prolidase activity of 2.
In BV-positive women, anti-Gvh IgA was inversely corre-
lated with sialidase (rs0.227; P 0.031); prolidase showed
a similar trend (rs  0.169; P  0.05).
We observed that very high levels of prolidase activity may
be associated with LBW. Prolidases are proteolytic enzymes
that facilitate matrix remodeling and cellular infiltration and
can modulate immune mediators (12, 21, 31). Several bacteria,
including G. vaginalis, are able to produce prolidases in vitro
(12, 27, 28).
We observed that detection of any sialidase activity is a
marker for increased LBW risk, regardless of knowledge of the
vaginal microbial condition. Sialidases are enzymes involved in
the pathogenesis of several diseases by cleaving sialic acid from
various glycoproteins and thus altering the immune response
(25, 33). Persistent sialidase activity after antibiotic treatment
has been associated with increased risk for LBW and PTD
(22). Other authors found no statistically significant associa-
tions (2).
Synergistic relationships between G. vaginalis and anaerobes
have been observed previously (7, 9, 15, 30). In this study,
concomitant G. vaginalis and anaerobe overgrowth was asso-
ciated with a high risk of poor pregnancy outcomes, especially
when women had low or no anti-Gvh IgA response.
In contrast, a high anti-Gvh IgA response appeared protec-
tive against LBW or PTD. High enzymatic activities are in-
versely correlated with a high anti-Gvh IgA response causing
impairment of the host mucosal defense (10, 11).
Our findings suggest an association between alteration of the
vaginal ecology (BV and/or G. vaginalis) and poor pregnancy
outcomes comprising two extreme profiles: (i) women with low
or no anti-Gvh IgA response plus high sialidase and/or proli-
dase activity (11.0% of women with BV [10 of 91]), in which
the host vaginal immune defense is overwhelmed by microbial
virulence factors, who have a higher risk for a poor outcome,
especially LBW; and (ii) women with a strong anti-Gvh IgA
response and low enzymatic activity (8.8% of women with BV
TABLE 1. Association between sialidase or prolidase activity levels and LBW or PTD
Measured parameter(s) and/or vaginal
colonization
% Positivea
NTD (n  116) LBW (n  116) PTD (n  86)
BV 14.6 20.7, 1.5 (0.9–2.6) 12.8, 0.9 (0.4–1.7)
G. vaginalis 36.2 42.2, 1.3 (0.8–2.0) 36.0, 1.0 (0.6–1.6)
BV and sialidase activity
1 (cutoff) 9.1 15.7, 1.9 (1.0–3.4)b 7.1, 0.8 (0.3–1.9)
2 1.0 3.5, 3.7 (0.9–15.1) 2.4, 2.5 (0.4–13.8)
G. vaginalis and sialidase activity
1 (cutoff) 11.0 18.3, 1.8 (1.0–3.2)b 11.8, 1.1 (0.5–2.2)
2 1.0 3.5, 3.7 (0.9–15.1) 2.4, 2.5 (0.5–13.8)
Sialidase activity
1 (cutoff) 15.3 28.7, 2.2 (1.4–3.6)b 20.0, 1.4 (0.8–2.5)
2 1.0 3.5, 3.7 (0.9–15.1) 2.4, 2.5 (0.4–13.8)
BV and prolidase activity
1 (cutoff) 13.5 18.6, 1.5 (0.8–2.5) 12.0, 0.9 (0.4–1.8)
2 0.2 2.7, 11.3 (1.2–109.6)b 1.2, 5.0 (0.3–81.5)
G. vaginalis and prolidase activity
1 (cutoff) 23.4 31.0, 1.5 (0.9–2.3) 26.5, 1.2 (0.7–2.0)
2 0.7 4.4, 6.4 (1.5–27.0)b 3.6, 5.2 (1.0–26.0)b
Prolidase activity
1 (cutoff) 33.7 41.6, 1.4 (0.9–2.1) 34.9, 1.1 (0.6–1.7)
2 1.0 4.4, 4.8 (1.3–18.0)b 3.6, 3.9 (0.8–17.6)
a Where two values are given, the second value is the OR. Values in parentheses are 95% CIs.
b P  0.05.
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[8 of 91]) who are not at risk for an adverse outcome. Deter-
mination of markers in vaginal fluid could help in the planning
of prevention strategies (18).
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